Skip to main content

RTW Investments — Portfolio, Page 4

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

107
Companies
$13.3B
Total invested
$131.3M
Avg. check
13
Industries
Biotechnology 23Health Care 13Medical 9Pharmaceutical 9Therapeutics 9Biopharma 6+7 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 7396 of 107
Oruka Therapeutics
September 2025

Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.

Biotechnology · Waltham$180.0M Post Ipo Equity
Mineralys Therapeutics
September 2025

Mineralys Therapeutics is a clinical-stage biopharmaceutical company committed to developing therapy for the treatment of hypertension.

Biopharma · Radnor$287.5M Post Ipo Equity
Arvinas
August 2025

Arvinas advances therapies degrading disease-causing proteins for life-threatening diseases, from discovery to commercialization.

Biotechnology · New HavenPost Ipo Equity
Alcyone Therapeutics
April 2025

Alcyone Therapeutics is Pioneering Next-Generation Precision CNS Genetic Therapies to unlock new possibilities

Biotechnology · LowellCorporate Round
AIRNA
April 2025

AIRNA develops RNA editing technologies to create medicines for various diseases.

Biotechnology · Cambridge$155.0M Series B
GH Research
February 2025

GH Research is a biopharmaceutical company developing novel therapies for the management of mental illness.

Biopharma · Dublin$150.0M Post Ipo Equity
Third Harmonic Bio
January 2025

Third Harmonic Bio is a clinical-stage company developing a first-in-class, highly selective, and oral kit inhibitor.

Biotechnology · Cambridge$3.9M Post Ipo Equity
Umoja Biopharma
January 2025

Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer.

Biopharma · Seattle$100.0M Series C
Windward Bio
January 2025

Windward Bio develops monoclonal antibodies for advanced immunological diseases.

Biotechnology · Basel$200.0M Series A
Numab
January 2025

Numab is a biotechnology company that offers antibody-based therapeutics for the treatment of severe diseases.

Biopharma · Wadenswil$54.8M Series C
Alesta Therapeutics
January 2025

Alesta Therapeutics focused on translating novel targets in the chronic stress response pathways into new therapeutic.

Biotechnology · Leiden$67.0M Series A
Ottimo Pharma
December 2024

Ottimo Pharma develops innovative cancer therapies using PD1-VEGFR2 antibodies.

Biotechnology · Sandwich$140.0M Series A
Beta Bionics
November 2024

Beta Bionics is a biotechnology company that provides software to reduce the burden of diabetes care.

Biotechnology · Irvine$60.0M Series E
Neurogene
November 2024

Neurogene is a developer of genetic medicines intended to improve patient outcomes for neurological disorders.

Biotechnology · New York$200.0M Post Ipo Equity
Aktis Oncology
September 2024

Aktis Oncology is a biotechnology company that designs and develops novel class radiopharmaceuticals.

Biotechnology · Boston$175.0M Series B
Ventyx Biosciences
September 2024

Ventyx is a biopharmaceutical company focused on advancing oral therapies for patients living with autoimmune and inflammatory disorders.

Biopharma · San Diego$27.0M Post Ipo Equity
LENZ Therapeutics
July 2024

LENZ Therapeutics operates as an organization engaged in the late-stage clinical development of pharmaceuticals for the eyes.

Health Care · Del Mar$30.0M Post Ipo Equity
Santa Ana Bio
June 2024

Santa Ana Bio is a biotechnology company focusing on precision immunology for autoimmune and inflammatory diseases.

Biotechnology · Alameda$125.0M Series B
CARGO Therapeutics
May 2024

CARGO Therapeutics develops an adoptive cell therapy to benefit patients from potentially curative treatment options.

Biotechnology · San Mateo$110.0M Post Ipo Equity
Lycia Therapeutics
May 2024

Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras.

Biotechnology · South San Francisco$106.6M Series C
Cullinan Therapeutics
April 2024

Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics used to end a drug program quickly.

Biopharma · Cambridge$280.0M Post Ipo Equity
Stoke Therapeutics
March 2024

Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for treatment.

Biotechnology · Bedford$125.0M Post Ipo Equity
Basking Biosciences
January 2024

Basking Biosciences is to commercialize technology developed at Duke and Ohio State Universities.

Biotechnology · Durham$55.0M Series A
Rocket Pharmaceuticals
September 2023

Rocket Pharmaceuticals is a biotech company that develops a pipeline of genetic therapies for rare childhood disorders.

Biotechnology · Cranbury$175.0M Post Ipo Equity

Where RTW Investments invests

Biotechnology23
Health Care13
Medical9
Pharmaceutical9
Therapeutics9
Biopharma6

About RTW Investments's portfolio

How many companies has RTW Investments invested in?

RTW Investments has invested in 107 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does RTW Investments invest in?

RTW Investments's top investment sectors include Biotechnology, Health Care, Medical, Pharmaceutical, Therapeutics. The firm invests across 13 different industry categories.

What is RTW Investments's largest investment?

Among tracked funding rounds, Mineralys Therapeutics received $287.5M in a Post Ipo Equity round. RTW Investments's total known invested capital is $13.3B.

What is the average investment size for RTW Investments?

RTW Investments's average investment size is $131.3M across its portfolio of 107 companies.

What are RTW Investments's most recent investments?

Recent RTW Investments portfolio additions include Oruka Therapeutics, Mineralys Therapeutics, Arvinas, Alcyone Therapeutics, AIRNA. These companies were founded in 2020 or later.

Reach the founders behind these 107 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →